Llwytho...
Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy
BACKGROUND: Apatinib, a small‐molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR‐2), has proven to be effective and safe for treating patients with advanced gastric cancer after second‐line chemotherapy failure. As VEGFR‐2 targeted therapy has made encouraging progress for th...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Thorac Cancer |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley & Sons Australia, Ltd
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166085/ https://ncbi.nlm.nih.gov/pubmed/30126078 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12836 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|